November 16, 2017
FDA: Baxter recalls one lot of injectable amiodarone
Editor's Note
The Food and Drug Administration (FDA) on November 15 announced the recall by Baxter International (Deerfield, Illinois) of one lot of Nexterone (amiodarone HCL) 150 mg/100 mL premixed injection because of the presence of particulate matter.
The particulate matter was identified as polyethylene, the primary constituent of the film and ports used to manufacture the bag in which the Nexterone is packaged.
The recalled lot (number NC109925) was distributed between August 23 and October 2, 2017.
Posted 11/15/2017] AUDIENCE: Pharmacy, Cardiology, Risk Manager ISSUE: Baxter International announced it is voluntarily recalling one lot of Nexterone (amiodarone HCl) 150 mg/100 mL Premixed Injection - distributed between 6/23/2017 and 10/2/2017 in the United States to wholesalers/distributors and healthcare facilities - due to the potential presence of particulate matter.
Free Daily News
- Report: Consistent, purposeful manager-team engagement reduces RN turnover
- Death, hospital readmission less likely for women treated by female doctors
- FDA announces class 1 recalls for infusion pumps, anesthesia workstation
- Study finds workforce readiness gap in new nurses
- Joint replacement manufacturer recalls products after FDA packaging warning
- Gene-edited pig kidney, heart pump combined in transplant surgery milestone
- Catheter sterility concerns prompt Class 1 FDA recall for surgery trays
- Large amounts of personal data possibly stolen in Change Healthcare cyberattack
- AI model helps predict patient decline, drive collaborative care
- One patient’s recovery highlights benefits of outpatient endoscopic spine surgery
© Access Intelligence, LLC. All rights reserved. | Privacy Policy | Diversity, Equity, Inclusion & Belonging